Lopez-Knowles, Elena
Detre, Simone
Hills, Margaret
Schuster, Eugene F.
Cheang, Maggie C. U.
Tovey, Holly
Kilburn, Lucy S.
Bliss, Judith M.
Robertson, John
Mallon, Elizabeth
Skene, Anthony
Evans, Abigail
Smith, Ian
Dowsett, Mitch
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-020-040)
Article History
Received: 18 February 2022
Accepted: 27 August 2022
First Online: 12 September 2022
Declarations
:
: Patients provided written informed consent before enrolment. POETIC was approved by the London–South East Research Ethics Committee (reference 08/H1102/37).
: M.C.U.C. has a patent for Breast Cancer Classifier: US Patent No. 9,631,239 with royalties paid and receive research funding from NanoString Technologies and veracyte advisory role. MD receives honoraria from Myriad Genetics and is a consultant and advisory board member of GTx, Radius Health, Orion Pharma, Lilly, Agile and Astrazeneca, has received funding from Pfizer (Inst) and Radius Health (Inst) and has been paid expenses from Pfizer and Myriad Genetics. JMB reports grants from Cancer Research UK, during the conduct of the study; grants from Medivation; grants and non-financial support from AstraZeneca, Merck Sharp & Dohme, Puma Biotechnology, Clovis Oncology, Pfizer, Janssen-Cilag, Novartis, and Roche, outside the submitted work. LK reports grants from Cancer Research UK, during the conduct of the study. HT received salary from Bayer. All other authors declare no competing interests.